Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Selected as Preferred Service Provider for Cancer Research UK

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina today announced it has been selected as a preferred service provider for Cancer Research UK.

As a result, Illumina will provide a range of services, starting with whole genome sequencing, to support the International Cancer Genome Consortium, which aims to develop a comprehensive description of genomic, transcriptomic, and epigenomic changes in 50 different tumor types and/or subtypes of clinical and societal importance.

Illumina and Cancer Research UK will initially focus their efforts on esophageal and prostate cancers, and potentially up to 1,500 whole human genome samples could be sequenced over a three-year period as part of the project. Illumina's HiSeq 2000 platform will be used to perform the whole genome sequencing.

As part of the collaboration, Illumina will also provide expression and epigenetic services for detailed characterization of transcriptomic and epigenomic changes in the target tumor types.

Additional terms of the deal were not released.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.